Bayer ESMO virtual media event / September 12^th, 2024,
4-5am (Sao Paulo), 9-10am CET (Europe), 3-4pm CST (Beijing)

Advancing Prostate Cancer Treatment

We are delighted to be hosting an exclusive virtual media event ahead of this year’s European Society for Medical Oncology (ESMO) congress, to highlight the challenges and opportunities to advance outcomes for people living with metastatic hormone-sensitive prostate cancer (mHSPC). We will present detailed results from the Phase III ARANOTE trial in mHSPC. Please note: the event will be held under embargo.

You will have a unique opportunity to hear first-hand insights on the new data from our multi-disciplinary panel of experts. This will be followed by a live Q&A session and an opportunity for one-to-one interviews with the panel post-event.

Speakers include:

Dr Fred Saad, FRCSC

Professor and Chief of Urology and Director of GU Oncology, University of Montreal

Tom

Former urologist living with mHSPC

Dr Iris Kuss

Head, Global Development, Darolutamide, Bayer

For any questions, please contact Malena Johannes (Global Communications Oncology): malena.johannes@bayer.com

About Prostate Cancer at Bayer

Bayer is committed to delivering science for a better life by advancing a portfolio of innovative treatments. The company has the passion and determination to develop new medicines that help improve and extend the lives of people living with cancer. Prostate cancer is the second most commonly diagnosed cancer in men and a key area of focus for Bayer. The company’s franchise includes two products on the market (Nubeqa™ and Xofigo™) and several compounds in development. Bayer is focused on addressing the unique needs of patients with prostate cancer, providing treatments that extend their lives throughout the different stages of the disease and allowing them to continue with their everyday activities, so that patients can live longer, better lives.

Forward-Looking Statements

This event may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.